Biomarker testing helps get the right treatment to the right patient at the right time. Each person's cancer has a unique pattern of biomarkers. Progress in improving health outcomes increasingly involves precision medicine, which uses information about a person's genes or...

Dana-Farber Cancer Institute has joined with Massachusetts hospitals, physicians, and patient advocate community in supporting reforms of insurers' prior authorization policies to reduce unnecessary delays in patient care and relieve the administrative burden in the health...

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. In the early stages, pancreatic cancer often does not present any noticeable signs or symptoms. By the time symptoms do appear, the cancer has typically grown significantly or spread...

The Massachusetts Pediatric Palliative Care program supports critically ill children, young adults, and their families, including children with disabilities and life-threatening and life-limiting diagnoses such as cancer. The program provides services that address the unmet...

Dana-Farber is a member of the Health Equity Compact (HEC), a statewide coalition created to address health disparities in Massachusetts. The HEC legislation proposes innovative solutions and structural reforms to address racial justice and health equity across the...

According to the American Cancer Society, prostate cancer is the second leading cause of death among men in the United States, with approximately 1 in 8 being diagnosed during their lifetime. However, an individual’s risk can vary based on factors like age, race, and family...